NA
CYTK icon

Neuburgh Advisers’s Cytokinetics CYTK Stock Holding History

Neuburgh Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$115K Hold
10,098
– – ﹤0.01% 779
2019
Q2 		$114K Hold
10,098
– – ﹤0.01% 785
2019
Q1 		$82K Buy
10,098
+3,322
+49% +$24.4K ﹤0.01% 806
2018
Q4 		$43K Buy
6,776
+2,420
+56% +$17.8K ﹤0.01% 836
2018
Q3 		$43K Buy
4,356
+2,046
+89% +$16.4K ﹤0.01% 860
2018
Q2 		$19K Buy
+2,310
New +$19.2K ﹤0.01% 872

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Neuburgh Advisers's CYTK Position: Q3 2019 in Review

Neuburgh Advisers held its Cytokinetics (CYTK) position steady in Q3 2019 at 10,098 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #779.

Neuburgh Advisers first reported a position in CYTK in Q2 2018 and has held it in 6 quarters since. 148 funds tracked by Wall St. Rank hold CYTK as of Q3 2019.

  • Neuburgh Advisers held 10,098 shares of Cytokinetics worth $115K as of Q3 2019.
  • Neuburgh Advisers left its Cytokinetics share count unchanged in Q3 2019.
  • Cytokinetics made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #779 holding.
  • Neuburgh Advisers first reported a position in Cytokinetics in Q2 2018 and has held it in 6 quarters since.
  • 148 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.